ArticleCancer chemotherapy and pharmacology2022

Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial.

Amita Patnaik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.